Drug development is usually seen as following a more or less linear path from publicly subsidized basic research to costly preclinical and clinical research by for-profit firms, which usually fails but occasionally succeeds in bringing highly profitable drugs to market. This study describes an additional feedback process in which pharmaceutical drugs serve as research tools. Diverse examples illustrate that the tools function of pharmaceuticals supports important advances in basic research. These often lead in turn to practical uses including new drug development.
MerrillSLevinRCMyersMB, eds. A Patent System for the 21st Century. Washington, DC: National Academy Press; 2004:110–111.
2.
FerraraN. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.
3.
FurmanJLMagaretKKIainMCockPublic & Private Spillovers, Location and the Productivity of Pharmaceutical Research. NBER Working Paper No. 12509. Sept. 2006.
4.
BercovitzJLMaryannPF. Fishing upstream: Firm innovation strategy and university research alliances. Res Policy. 2007;36:930–948.
5.
SteinbergD. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res. 2006;47:1339–1351.
6.
TopolE.Editorial: Intensive Statin therapy: a sea change in cardiovascular prevention. N Engl J Med. 2004;350:1562–1564.
7.
CannonCP. Editorial, the IDEAL cholesterol: lower is better. JAMA. 2005;294:2492–2494.
HauserSLEmmanuelleWDouglasLAB-cell depletion with Rituximab in relapsing–remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.
11.
McFarlandHF. The B cell – old player, new position on the team. N Engl J Med. 2008;358:664–665.
12.
FolkmanJ. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
13.
SeifeC.Breakthrough of the year. Illuminating the dark universe. Science. 2003;302:2038–2039.
14.
FerraraNKennethJHWilliamNDiscovery and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
15.
SemenzaGL. A new weapon for attacking tumor blood vessels. N Engl J Med. 2008;358:2066–2067.
16.
VlahakisSRBrenGDAlgeciras-SchimnichAFlying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Clin Pharmacol Ther. 2007;82:294–299.
17.
HavlirDV.Editorial: HIV integrase inhibitors — out of the pipeline and into the clinic. N Engl J Med. 2008;359:416–418.
18.
CullenMThatcherN.Comment: Gefitinib or Docetaxel in advanced non-small-cell lung cancer. Lancet. 2008;372:1785–1786.
FunderJW. Aldosterone, sodium, and hypertension: lessons from Torcetrapib?Hypertension. 2010;55:221–223.
21.
BarterPJNichollsSRyeKAntiinflammatory Properties of HDL. Circ Res. 2004;95:764–772.
22.
StewartJB. Mistakes aside, Pfizer deserves praise -- not scorn. Wall Street Journal. December13, 2006: D3.
23.
FunderJW. The off-target effects of Torcetrapib. Endocrinology. 2009;150:2024–2026.
24.
HuXDietzJDXiaCTorcetrapib induces Aldosterone and Cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009;150:2211–2219.
25.
ForrestMJBloomfieldDBriscoeRJTorcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465–1473.
26.
JoyTHegeleRA. Is raising HDL a futile strategy for atheroprotection?Nat Rev Drug Discov. 2008;7:143–155.
27.
CitronM. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387–398
28.
KolataG. Doubt on tactic in Alzheimer’s battle. New York TimesAug 19, 2010.
29.
Wyss-CorayT. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?Nat Med. 2006;12:1005–1015.
30.
KleinWL. Cytotoxic Intermediates in the fibrillation pathway: Aβ oligomers in Alzheimer’s disease as a case study. In: UverskyVNFinkAL, eds. Volume 4: Protein Misfolding, Aggregation, and Conformational Diseases, Part A: Protein Aggregation and Conformational Diseases. New York: Springer Science+Business Media; 2006:61–82.
31.
HolmesC. (2008) Long-term effects of Aβ42immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–223.
PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2: e73.
34.
YangQGrahamTEModyNSerum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–362.
35.
MankouriaJPhilipRTSarahGEnhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci U S A. 2010;107:11549–11554.
36.
MarascoWSuiJ. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007;25:1421–1434.
